Australian Clinical Labs Ltd (ACL) Stock Statistics & Valuation Metrics

Australian Clinical Labs Ltd has a market cap or net worth of AUD 606.19M. The enterprise value is AUD 741.17M.

Market Cap

AUD 606.19M

Enterprise Value

AUD 741.17M

Australian Clinical Labs Ltd has 186,518,980 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

186,518,980

Owned by Insiders

0.02%

Owned by Institutions

8.23%

Australian Clinical Labs Ltd’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 8.04%.

Return on Equity (ROE)

0.16

Return on Assets (ROA)

0.04

Return on Invested Capital (ROIC)

8.04%

Return on Capital Employed (ROCE)

0.16

Revenue Per Employee

162.12K

Profits Per Employee

5,269.111

Employee Count

4,500

Asset Turnover

1.23

Inventory Turnover

40.66

The current PE Ratio of Australian Clinical Labs Ltd is 26.66. Australian Clinical Labs Ltd’s PEG ratio is -0.80.

PE Ratio

26.66

PS Ratio

0.84

PB Ratio

4.21

Price to FCF

4.00

Price to Operating Cash Flow

3.86

PEG Ratio

-0.80

In the last 12 months, Australian Clinical Labs Ltd had revenue of 729.52M and earned 23.71M in profits. Earnings per share was 0.12.

Revenue

729.52M

Gross Profit

150.21M

Operating Income

61.49M

Pretax Income

37.39M

Net Income

23.71M

EBITDA

196.84M

Earnings Per Share (EPS)

0.12

In the last 12 months, operating cash flow was 163.31M and capital expenditures -9.58M, giving a free cash flow of 153.73M billion.

Operating Cash Flow

163.31M

Free Cash Flow

153.73M

Free Cash Flow per Share

0.80

Australian Clinical Labs Ltd pays an annual dividend of AUD 0.04, resulting in a dividend yield of 3.92%

Dividend Per Share

AUD 0.04

Dividend Yield

3.92%

Payout Ratio

69.67%

Free Cash Flow Yield

24.83%

Earnings Yield

3.74%

Beta

0.90

52-Week Price Change

25.81%

50-Day Moving Average

2.89

200-Day Moving Average

2.32

Relative Strength Index (RSI)

72.47

Average Volume (3m)

700.34K

Australian Clinical Labs Ltd upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 16, 2026

Next Earnings Date

Feb 23, 2027

Ex-Dividend Date

Mar 11, 2026

Australian Clinical Labs Ltd as a current ratio of 0.54, with Debt / Equity ratio of 225.66%

Current Ratio

0.54

Quick Ratio

0.47

Debt to Market Cap

0.40

Net Debt to EBITDA

1.59

Interest Coverage Ratio

3.33

In the past 12 months, Australian Clinical Labs Ltd has paid 13.38M in taxes.

Income Tax

13.38M

Effective Tax Rate

0.36

Australian Clinical Labs Ltd EV to EBITDA ratio is 4.80, with an EV/FCF ratio of 6.06.

EV to Sales

1.28

EV to EBITDA

4.80

EV to Free Cash Flow

6.06

EV to Operating Cash Flow

5.71

Australian Clinical Labs Ltd has AUD 25.66M in cash and marketable securities with AUD 337.40M in debt, giving a net cash position of -AUD 311.75M billion.

Cash & Marketable Securities

AUD 25.66M

Total Debt

AUD 337.40M

Net Cash

-AUD 311.75M

Net Cash Per Share

-AUD 1.67

Tangible Book Value Per Share

-AUD 0.08

Gross margin is 20.59%, with operating margin of 8.04%, and net profit margin of 3.25%.

Gross Margin

20.59%

Operating Margin

8.04%

Pretax Margin

5.13%

Net Profit Margin

3.25%

EBITDA Margin

26.59%

EBIT Margin

8.04%

The average price target for Australian Clinical Labs Ltd is AUD 2.88, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target

AUD 2.88

Price Target Upside

13.15% Downside

Analyst Consensus

Neutral

Analyst Count

3

Revenue Growth Forecast

-0.90%

EPS Growth Forecast

-25.09%

Smart Score

8

AI Score

54